GPT and Hepatic fibrosis: Administration of serum EVs to CCl4- or TAA-treated mice resulted in reduced hepatic fibrosis, hepatocyte death, inflammatory infiltration, circulating AST/ALT levels and hepatic or circulating pro-inflammatory cytokines whereas serum EVs from fibrotic mice were not therapeutic.